Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance

Peptides

Volumn 27, Issue 7, 2006, Pages 1659-1667

  Ong, Kwok Leung ^a   Wong, Louisa Y F ^a   Man, Yu Bun ^a   Leung, Raymond Y H ^a   Song, You Qiang ^a   Lam, Karen S L ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Haplotype; Hypertension; Insulin resistance; Metabolic syndrome; Single nucleotide polymorphism; Urotensin II

Indexed keywords

GLUCOSE; INSULIN; NEUROPEPTIDE RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ADULT; ARTICLE; CELL FUNCTION; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HAPLOTYPE; HONG KONG; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BASE SEQUENCE; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCOSE TOLERANCE TEST; HAPLOTYPES; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LINKAGE DISEQUILIBRIUM; MALE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS;

EID: 33745070225     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.02.008     Document Type: Article

References (48)

1. Affolter J.T., Newby D.E., Wilkinson I.B., Winter M.J., Balment R.J., and Webb D.J. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 54 (2002) 617-621
2. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
3. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
4. Baron A.D. Insulin resistance and vascular function. J Diabetes Complications 16 (2002) 92-102
5. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
6. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
7. Brand-Herrmann S.M., Kopke K., Reichenberger F., Schmidt-Petersen K., Reineke T., Paul M., et al. Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. J Hypertens 22 (2004) 1289-1297
8. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 341-344
9. Cheung B.M.Y., Lam T.H., Lam K.S.L., Tam S.C.F., Wat N.M.S., Man Y.B., et al. The Hong Kong cardiovascular risk factor prevalence survey cohort - results at 7 years. J Hypertens 22 (2004) S268-S269
10. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
11. Du W., Sun H., Wang H., Qiang B., Shen Y., Yao Z., et al. Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes. Chin Med J 114 (2001) 876-878
12. El-Atat F.A., Stas S.N., McFarlane S.I., and Sowers J.R. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 15 (2004) 2816-2827
13. Hill W.G., and Weir B.S. Maximum-likelihood estimation of gene location by linkage disequilibrium. Am J Hum Genet 54 (1994) 705-714
14. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 767-772
15. Janus E.D., Wat N.M.S., Lam K.S.L., Siu S.T.S., Liu L.J., Lam T.H., and For the Hong Kong Cardiovascular Risk Factor Steering Committee. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Diabet Med 17 (2000) 741-745
16. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
17. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
19. Mori Y., Otabe S., Dina C., Yasuda K., Populaire C., Lecoeur C., et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51 (2002) 1247-1255
20. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
21. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
22. Ong K.L., and Cheung B.M.Y. Urotensin II and the circulatory system. Hong Kong J Nephrol 7 (2005) 9-13
23. Ong K.L., Lam K.S.L., and Cheung B.M.Y. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19 (2005) 65-75
24. Protopopov A., Kashuba V., Podowski R., Gizatullin R., Sonnhammer E., Wahlestedt C., et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridisation. Cytogenet Cell Genet 88 (2000) 312-313
25. Rajala M.W., and Scherer P.E. The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
26. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
27. Richards A.M., Nicholls M.G., Lainchbury J.G., and Fisher S. Yandle TG Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
28. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
29. Shifman S., Kuypers J., Kokoris M., Yakir B., and Darvasi A. Linkage disequilibrium patterns of the human genome across populations. Hum Mol Genet 12 (2003) 771-776
30. Silvestre R.A., Egido E.M., Hernandez R., Leprince J., Chatenet D., Tollemer H., et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151 (2004) 803-809
31. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33 (2001) 379-381
32. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 (2004) H1597-H1602
33. Stephens M., and Donelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
34. Stephens M., Smith N., and Donelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
35. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
36. Sun H.X., Du W.N., Zuo J., Wu G.D., Shi G.B., Shen Y., et al. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 (2002) 223-227
37. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25 (2004) 1803-1808
38. Thomas G.N., Critchley J.A., Tomlinson B., Anderson P.J., Lee Z.S., and Chan J.C. Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism 49 (2000) 1523-1528
39. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104 (2003) 1-5
40. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
41. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S.O., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
42. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
43. Weir G.C., and Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 (2004) S16-S21
44. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
45. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
46. Wilkes J.J., Hevener A., and Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52 (2003) 1904-1909
47. Wilkinson I.B., Affolter J.T., de Haas S.L., Pellegrini M.P., Boyd J., Winter M.J., et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53 (2002) 341-347
48. Zhu F., Ji L., and Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 82 (2002) 1473-1475